MedTrace Logo

COVID-19 Vaccine For Indirect Protection

NCT04818736 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-05-14

No results posted yet for this study

Summary

The primary objective of this study is to test whether vaccinating adults ≥18 years in Hutterite colonies with mRNA-1273 (Moderna COVID-19) vaccine as compared to control (usual care) can prevent RT-PCR confirmed COVID-19 in non-vaccinated Hutterite members.

Conditions

  • Vaccine Preventable Disease

Interventions

BIOLOGICAL

COVID-19 Vaccination

Dose 1: 0.5 mL at Day 0 Dose 2: 0.5 mL at Day 28

OTHER

Usual care

Participants can receive the COVID-19 whenever they are eligible according to local provincial guidelines.

Sponsors & Collaborators

  • University of Alberta

    collaborator OTHER

  • University of Saskatchewan

    collaborator OTHER

  • University of Manitoba

    collaborator OTHER

  • McMaster University

    lead OTHER

Principal Investigators

  • Mark Loeb · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-15
Primary Completion
2021-09-30
Completion
2021-12-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04818736 on ClinicalTrials.gov